BMS-90011 is under clinical development by Bristol-Myers Squibb and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect BMS-90011’s likelihood of approval (LoA) and phase transition for Refractory Acute Myeloid Leukemia took place on 23 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
In addition, the same event on 23 Nov 2022 increased BMS-90011’s LoA and PTSR for Relapsed Acute Myeloid Leukemia.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their BMS-90011 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
BMS-90011 overview
BMS-90011 is under development for the treatment of relapsed and refractory Non-Hodgkin Lymphoma, metastatic castration-resistant prostate cancer (mCRPC), relapsed and refractory solid tumors including neuroendocrine carcinoma, squamous non-small cell lung cancer, small-cell lung cancer, and non-Hodgkin's lymphomas, relapsed and refractory acute myeloid leukemia (AML), acute myeloid leukemia, diffuse large B-cell lymphoma, follicular lymphoma (FL), marginal zone B-cell Lymphoma s including nodal marginal zone B-cell lymphoma, splenic marginal zone B-cell lymphoma, extranodal marginal zone B-cell lymphoma. It is administered orally. The drug candidate acts by targeting Lysine-specific demethylase 1 (LSD-1).
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.
Quick View BMS-90011 LOA Data
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Developers |
|
Highest Development Stage |
|